Weight Loss Estimator Calculator
Estimate Your Weight Loss Timeline
Enter your current weight and goal to see how long it might take to reach your target with different medications.
Your Estimate
Quick Takeaways
- Contrave combines naltrexone and bupropion to curb appetite and control cravings.
- GLP‑1 agonists like Wegovy and Saxenda often produce larger average weight loss but require injectable administration.
- Qsymia offers strong results but carries a higher risk of cardiovascular side effects.
- Costs vary widely; insurers may cover GLP‑1 drugs more often than oral combos.
- Choosing the right drug hinges on your health profile, tolerance for injections, and budget.
When it comes to prescription‑only weight‑loss aids, the market is crowded and confusing. Contrave is a tablet that mixes naltrexone and bupropion to reduce appetite and blunt cravings. Approved by the FDA in 2014, it’s marketed for adults with a body‑mass index (BMI) of 30 kg/m² or more, or 27 kg/m² with at least one weight‑related condition.
But Contrave isn’t the only option. New GLP‑1 receptor agonists, older combination pills, and even some off‑label uses compete for the same patient pool. This guide breaks down the key alternatives, compares efficacy, safety, dosing, and cost, and helps you figure out which drug aligns with your health goals.
How Contrave Works
The twin ingredients hit two different pathways:
- Naltrexone blocks opioid receptors in the hypothalamus, reducing the reward signals that drive overeating.
- Bupropion stimulates the release of dopamine and norepinephrine, curbing appetite through the central nervous system.
Clinically, patients on Contrave lose about 5-10 % of baseline weight after a year of therapy, assuming they pair the medication with lifestyle changes.
Top Oral and Injectable Alternatives
Below is a snapshot of the most widely prescribed rivals.
| Drug (Brand) | Active Ingredient(s) | Mechanism | Typical Weight‑Loss % (12 months) | Common Side Effects | Administration | FDA Status (2025) |
|---|---|---|---|---|---|---|
| Contrave | Naltrexone + Bupropion | Opioid‑receptor blockade + dopamine/norepinephrine release | 5-10 % | Nausea, headache, insomnia | Oral tablet, twice daily | Approved for chronic weight management |
| Wegovy | Semaglutide (2.4 mg) | GLP‑1 receptor agonist - slows gastric emptying, reduces appetite | 15-20 % | Nausea, vomiting, diarrhea, constipation | Weekly subcutaneous injection | Approved for obesity (BMI ≥ 30 or ≥ 27 with comorbidities) |
| Saxenda | Liraglutide (3.0 mg) | GLP‑1 receptor agonist - similar to Wegovy but daily dosing | 8-12 % | Nausea, pancreatitis risk, gallbladder disease | Daily subcutaneous injection | Approved for weight loss |
| Qsymia | Phentermine + Topiramate | Stimulates sympathetic nervous system + enhances satiety | 10-13 % | Elevated heart rate, insomnia, tingling | Oral capsule, once daily | Approved for chronic weight management |
| Mysimba | Naltrexone + Bupropion (EU brand) | Identical to Contrave - combines opioid blockade with dopamine release | 5-9 % | Same as Contrave | Oral tablet, twice daily | Approved in Europe, not sold in US |
Deep Dive: Efficacy and Real‑World Results
Clinical trials give us a baseline, but real‑world data tell a richer story.
GLP‑1 agonists (Wegovy, Saxenda) consistently outpace oral combos. A 2024 meta‑analysis of 12 trials found average weight loss of 17 % for semaglutide at the 2.4 mg dose, compared with 9 % for liraglutide 3 mg. The biggest driver is the strong appetite‑suppressing signal sent from the gut to the brain.
Contrave (and its EU counterpart Mysimba) delivers modest results - about 7 % on average - but its oral route makes it attractive for patients who hate needles. Success rates climb when the medication is paired with a structured behavioral program; one UK cohort reported 12 % loss after 18 months when diet counseling was mandatory.
Qsymia can achieve 12 % loss, but the risk profile is higher. A cardiovascular outcomes study in 2023 showed a slight uptick in heart‑rate‑related events among patients over 60, prompting clinicians to reserve it for younger, otherwise healthy individuals.
Safety Profiles: What to Watch For
Every drug carries trade‑offs. Below is a quick safety cheat‑sheet.
- Contrave: Monitor blood pressure and mood. Bupropion can raise seizure risk in people with a history of epilepsy.
- Wegovy: Watch for signs of gallbladder disease; rapid weight loss can precipitate stones.
- Saxenda: Pancreatitis, though rare, is a serious concern. Regular lipase checks are advisable.
- Qsymia: Contra‑indicated in uncontrolled hypertension and pregnancy.
- Mysimba: Same warnings as Contrave, plus the European label adds a caution for severe psychiatric disorders.
In practice, most patients tolerate these meds well if titrated slowly and paired with routine labs (CBC, metabolic panel, liver enzymes).
Cost Considerations in 2025
Price can be a deal‑breaker, especially in the UK where NHS coverage varies.
| Drug | Monthly Cost | Typical Insurance Coverage (US) |
|---|---|---|
| Contrave | 150 | 60 % (partial) |
| Wegovy | 1,300 | 80 % (high‑tier) |
| Saxenda | 950 | 70 % (partial) |
| Qsymia | 120 | 90 % (generic available) |
| Mysimba | 140 (EU price) | Varies by country |
In the UK, the NHS tends to list Wegovy and Saxenda under “high‑cost medicines” with strict eligibility. Contrave (or Mysimba) is more likely to be funded when other options fail, because it’s cheaper per tablet.
Choosing the Right Option for You
Here’s a quick decision tree you can run through with your clinician:
- Do you prefer pills over injections?
Yes → Consider Contrave, Qsymia, or Mysimba.
No → Look at GLP‑1 agonists. - Do you have a history of cardiovascular disease or high blood pressure?
Yes → Avoid Qsymia; GLP‑1 drugs are generally safer for heart patients. - Is rapid weight loss a priority (e.g., pre‑surgery)?
Yes → Wegovy offers the biggest drop. - Are you on other medications that interact with bupropion (e.g., MAO inhibitors)?
Yes → Skip Contrave/Mysimba. - Does your insurance or NHS plan cover injectable drugs?
Yes → GLP‑1 options become viable; otherwise, oral combos are more affordable.
Keep a notebook of side‑effects, weight changes, and any mood shifts. Sharing this data at each follow‑up helps the doctor fine‑tune your regimen.
Practical Tips for Maximizing Results
- Start low, go slow: All these meds have titration schedules. Jumping to full dose can cause nausea and early dropout.
- Pair with behavior therapy: Cognitive‑behavioral programs boost the average loss by 2‑3 % across the board.
- Watch your diet quality: High‑protein meals reduce hunger spikes that some drugs (especially Qsymia) can’t fully control.
- Stay active: Even moderate walking improves insulin sensitivity and enhances GLP‑1 effects.
- Routine labs: Get a baseline metabolic panel before starting, then repeat every 3 months.
Frequently Asked Questions
Can I take Contrave and Wegovy together?
No. Both drugs affect appetite through overlapping pathways and increase the risk of severe nausea, blood‑pressure changes, and serotonin syndrome. Choose one based on your preference for pills versus injections.
Is Contrave safe for people with a past history of depression?
Bupropion is actually an antidepressant, but it can also cause mood swings in some individuals. A thorough psychiatric evaluation is recommended before starting.
How long do I stay on a weight‑loss medication?
Most guidelines suggest at least 6‑12 months of continuous therapy, followed by a reassessment. If you maintain a ≥ 5 % loss and keep a healthy BMI, a gradual taper may be possible.
Are there natural alternatives that work as well as Contrave?
Lifestyle changes alone can achieve 3-5 % loss, but no over‑the‑counter supplement matches the clinically proven efficacy of prescription combos. Some people combine green tea extract with a low‑calorie diet, but results are modest.
What should I do if I experience severe nausea on Wegovy?
Slow the titration speed. Take the injection with a small snack and stay hydrated. If nausea persists beyond the first 4 weeks, discuss dose reduction or switching to another agent with your doctor.
Whether you’re leaning toward an oral pill like Contrave or an injection such as Wegovy, the key is to treat the medication as a tool-not a miracle. Pair it with realistic diet tweaks, regular activity, and professional support, and you’ll give yourself the best shot at lasting weight loss.
Weight loss drugs each carry their own story of promise.
Contrave sits between pills and injections as a middle ground.
Its blend of naltrexone and bupropion attacks appetite from two angles.
The reality is that the average loss hovers around seven percent.
That number feels modest when you compare it to the twenty percent from semaglutide.
Yet the oral route can be a deciding factor for needle‑phobic patients.
The medicine also whispers about mood changes because bupropion is an antidepressant.
Doctors must watch blood pressure as the drug can raise it in some users.
Real‑world data shows that pairing Contrave with behavioral therapy lifts results.
One study from the UK reported twelve percent loss after eighteen months with mandatory counseling.
The side effects list reads nausea headache insomnia and occasional dizziness.
Compared with GLP‑1 agents the gastrointestinal upset is milder.
Cost remains a barrier with monthly prices near one hundred and fifty dollars.
Insurance coverage varies but many plans only reimburse a portion.
In the end the choice rests on personal comfort with daily tablets versus weekly shots.
While the discussion acknowledges the efficacy of oral agents it is essential to recognise the regulatory framework governing their prescription. Contrave has obtained FDA approval for chronic weight management and must be prescribed alongside lifestyle interventions. The clinician’s role includes monitoring hepatic function and blood pressure throughout therapy.
Honestly this whole table looks like a marketing brochure not a real guide. If you’re looking for a magic pill you’ll be dissappointed. Contrave is just okay – it’s not a miracle and the side effects are often ignored in the hype. People love the “no needle” angle but forget that bupropion can cause seizures in folks with a history of epilepsy. The data you quoted for semaglutide is out of this world and makes Contrave look like a cheap knockoff. Stop thinking that any drug will replace hard work.